Reverse-turn mimetics and method relating thereto
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
1. A compound having the following general formula (VII)
—Y—R 10 (VI)
wherein (VI) is the formula:
wherein when not linked to R 10 ,
R a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; or a bicyclic aryl group having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur;
R b is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and aryl ring in the compound may have one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups;
Rc is a saturated or unsaturated C 1-6 alkyl, C 1-6 alkoxy, perfluoro C 1-6 alkyl group; and
X 1 , X 2 , and X 3 may be the same or different and independently selected from hydrogen, hydroxyl, and halide; and
Wherein one of R a , R b , R c , X 1 , X 2 , and X 3 is linked to R 10 via Y,
Y is an oxygen, sulfur, or nitrogen in R a , R b , and R c , or an oxygen in X 1 , X 2 and X 3 ; and
Y—R 10 is hemimalate, dimethylaminoalkylcarbamates, or a salt thereof; or R 10 is hydroxyalkyl, glycosyl, substituted or unsubstituted piperidine oxycarbonyl, or a salt thereof.
2. A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable carrier.
3. The compound of claim 1 , wherein when not linked to R 10 ,
R a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C 1-4 alkylamino, C 1-4 dialkylamino, halogen, perfluoro C 1-4 alkyl, C 1-3 alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; a naphthyl group; a quinolinyl group; an indazolyl group; or a benzpyrazolyl group; an isoquinolinyl group; and
R b is phenyl, pyridyl or piperidyl, all of which may be substituted with one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups.